Skip to main content
. 2017 Mar 6;21:45. doi: 10.1186/s13054-017-1633-1

Table 2.

Duration of treatment, overall hospital survival and survival by week of ECMO termination

Overall survival (95% confidence interval) Survival at weeks 1, 2 and 3
Clinical category Number Median duration (h) IQR Week 1 Week 2 Week 3+
Medical: non-cardiac 115 87 31–170 49.6% (40.6–58.6) 53.5% (43.0–63.7) 42.8% (24.5–63.5) 25.0% (7.1–59.1)
Medical: other cardiac disease 383 96 48–162 38.4% (33.6–43.3) 37.0% (31.7–42.7) 42.0% (31.1–53.8) 47.1% (26.2–69.0)
Medical: structural heart disease 296 117 58–192 44.3% (38.7–50.0) 43.1% (36.4–50.0) 50.7% (39.3–62.0) 34.8% (18.8–55.1)
Medical: myocarditis 87 154 96–230 64.4% (53.9–73.6) 70.6% (57.0–81.3) 62.5% (42.7–78.8) 41.7% (19.3–68.0)
Medical: coronary artery disease 424 109 51–177 40.1% (36.0–45.3) 40.6% (35.3–46.2) 42.2% (32.1–52.9) 35.5% (21.1–53.1)
Surgical: post VAD 117 68 33–122 41.9% (33.3–50.9) 41.0% (32.0–50.5) 44.4% (18.9–73.3) 66.7% (20.8–93.9)
Surgical: post heart transplantation 175 108 66–173 57.1% (49.7–64.2) 60.0% (51.4–68.0) 52.9% (36.7–68.6) 36.3% (15.2–64.6)
Surgical: other cardiac 972 87 41–146 35.9% (33.0–39.0) 38.7% (35.3–42.1) 25.3% (19.0–33.0) 20.0% (10.5–34.8)
Overall 2699 96 47–164 41.4% (39.5–43.3) 42.5% (40.4–44.7) 39.2% (34.9–43.6) 32.9% (26.0–40.6)

IQR interquartile range, VAD ventricular assist device